Investment Rating - The industry investment rating is "Positive" (maintained) [1] Core Insights - The report highlights that the price adjustment by Laopu Gold exceeded expectations, reinforcing its high-end brand positioning. The price increase for most products ranged from 20% to 30%, significantly higher than previous adjustments [5][27] - The report emphasizes the shift in consumer demand towards self-wearing and aesthetic-driven purchases, suggesting that brands with differentiated product offerings are likely to navigate price increases more smoothly [31] Summary by Sections Industry Trends - The retail and social service indices reported a decline of 1.64% and an increase of 1.68% respectively during the week from February 24 to February 27, 2026. The retail index ranked 30th among 31 primary industries [7][16] - The jewelry sector has shown the highest growth, with a year-to-date increase of 10.59% [19] Investment Recommendations - Investment Theme 1: Focus on high-end gold and fashion jewelry brands, recommending Laopu Gold and Chaohongji, with beneficiaries including Liu Fu Group and Zhou Shengsheng [8][33] - Investment Theme 2: Highlighting retail companies adapting to trends and AI-enabled cross-border e-commerce leaders, recommending Yonghui Supermarket and Aiyingshi [8][33] - Investment Theme 3: Emphasizing beauty brands that meet emotional value and safety ingredient innovation, recommending Maogeping and Pola [8][33] - Investment Theme 4: Focusing on differentiated medical beauty product manufacturers and leading medical beauty institutions, recommending Meilitiantian Medical Health and Aimeike [8][33] Company-Specific Insights - Laopu Gold reported a revenue of 12.354 billion yuan for the first half of FY2025, a year-on-year increase of 250.9%, with a net profit of 2.268 billion yuan, up 285.8% [35] - Chaohongji is expected to achieve a net profit of 436 to 533 million yuan in 2025, reflecting a growth of 125% to 175% [35] - Yonghui Supermarket is projected to have a net profit of -2.14 billion yuan in 2025, indicating a significant operational challenge [35] - Meilitiantian Medical Health anticipates a net profit growth of no less than 34% in 2025, showcasing strong resilience and potential for growth [43]

Group 1 - The core viewpoint of the article is that the company, Aimeike, currently has no specific plans or developments in AI-assisted research and development [1] Group 2 - Investors have inquired about Aimeike's initiatives in AI-assisted R&D on an investor interaction platform [1] - Aimeike responded to the inquiry on February 26, confirming the absence of any AI-assisted R&D initiatives to date [1]

Group 1 - The company, Aimeike (300896.SZ), has stated that it currently does not have any plans for AI-assisted research and development [1]

Group 1 - The core point of the article is that the company Aimeike reported that as of February 10, 2026, the number of its shareholders reached 61,417 [2]

Core Viewpoint - The competition for the代理权 of "童颜针" has intensified, with 江苏吴中 facing significant challenges after its delisting, while 爱美客's performance remains concerning amid ongoing disputes [1][10]. Group 1: 江苏吴中 Developments - 江苏吴中 plans to transfer 100% of its subsidiary, 上海吴中美学, for 80 million yuan to alleviate cash flow issues and address debt pressures [2][3]. - The subsidiary, 上海吴中美学, reported total assets of approximately 104 million yuan and a net loss of about 21.83 million yuan for the period from January to November 2025 [3]. - 江苏吴中 was forced to delist at the end of 2025 due to violations including false disclosures and inflated revenue, with a cumulative inflated revenue of approximately 1.771 billion yuan from 2020 to 2023 [4]. Group 2: 爱美客 Performance - 爱美客's revenue for the first three quarters of 2025 was 1.865 billion yuan, a year-on-year decline of 21.49%, with a net profit decrease of 31.05% to 1.093 billion yuan [10]. - The company experienced a 30.12% drop in net cash flow from operating activities compared to the previous year, amounting to 1.073 billion yuan [10]. Group 3: Industry Context - 江苏吴中 initiated its medical beauty segment in April 2021, aiming to expand its presence in the industry, which included acquiring exclusive distribution rights for the AestheFill product [5][6]. - The partnership with Regen for the AestheFill product faced challenges when 爱美客 acquired a majority stake in Regen, leading to a dispute over distribution rights [8][9].

Investment Rating - The industry investment rating is "Positive" (maintained) [1] Core Viewpoints - The report highlights a steady recovery in consumer spending during the Spring Festival, with significant increases in payment transactions and retail sales compared to the previous year [4][26] - The report emphasizes the importance of high-quality companies in high-growth sectors driven by emotional consumption themes [7][35] Summary by Sections Industry Dynamics - The Spring Festival saw a robust recovery in social consumption, with payment transactions on New Year's Eve reaching 4.931 billion, a 21.64% increase from the previous year [4][26] - Key regions like Hainan and cities such as Tianjin and Zhenjiang showed strong performance in retail and dining, with Hainan's duty-free shopping amounting to 1.03 billion yuan, up 20.9% year-on-year [4][27] - Domestic travel orders surged by 60%, and outbound travel orders increased by over 180% during the holiday period [4][26] Investment Recommendations - Investment Theme 1: Focus on high-end gold and fashion jewelry brands, recommending companies like Laopai Gold and Chaohongji for their differentiated product offerings [7][35] - Investment Theme 2: Emphasize retail companies adapting to trends and AI-enabled cross-border e-commerce leaders, with recommendations for Yonghui Supermarket and Aiyingshi [7][35] - Investment Theme 3: Highlight domestic beauty brands that cater to emotional value and innovative safe ingredients, recommending brands like Maogeping and Proya [7][35] - Investment Theme 4: Focus on differentiated medical beauty product manufacturers and leading medical beauty institutions, recommending companies like Meilitiantian Medical Health and Aimeike [7][35] Market Performance - The retail and social service indices reported declines of 1.59% and 0.78% respectively during the week from February 9 to February 13, 2026 [6][15] - The report notes that the education sector saw the highest growth among sub-sectors, while the watch and jewelry sector led the year-to-date performance with an 11.29% increase [6][18] Company Highlights - Laopai Gold reported a significant revenue increase of 250.9% in the first half of FY2025, driven by strong consumer demand and brand expansion [37] - Chaohongji is expected to achieve a net profit growth of 125% to 175% in FY2025, supported by its differentiated product strategy [37] - Maogeping and Proya are highlighted for their strong performance in the beauty sector, with Maogeping achieving a revenue increase of 31.3% in FY2025 [37]

Group 1 - The core point of the article is that the recent US Supreme Court ruling on the $175 billion tariff refund has significant implications for both China and the A-share market, despite the refund being an internal US matter [2][6][28] - The $175 billion in tariffs was primarily collected from imports, including a 10% tariff on Chinese goods, and is now being refunded to US importers [8][10] - The refund will indirectly benefit Chinese companies as US importers, who have been financially strained by tariffs, will use the refunded money to pay off debts to Chinese suppliers and resume orders [12][14][28] Group 2 - The immediate impact on the A-share market is expected to be positive, with a potential "opening red" for A-shares as market sentiment improves following the ruling [40][46] - The ruling is seen as a signal that the previous high tariffs on Chinese goods may not be a permanent state, which could lead to a more favorable environment for Chinese exports [20][48] - Structural opportunities in the A-share market are identified, focusing on five main lines: export-oriented sectors, domestic substitution, strategic resources, domestic consumption, and new energy [51][62][88] Group 3 - Export-oriented sectors, particularly those with high exposure to the US market, are expected to benefit directly from the tariff refunds, with companies like Midea Group and Haier expected to see improved performance [52][72][73] - Domestic substitution and self-sufficiency in sectors like semiconductors and military equipment are highlighted as long-term strategic focuses, with companies like SMIC and AVIC Shenyang Aircraft being key players [53][78][86] - Strategic resources such as rare earths and gold are also expected to see price support due to ongoing global supply chain disruptions, benefiting companies like Northern Rare Earth and Shandong Gold [56][87]

Core Insights - The Chinese medical beauty market is experiencing a significant shift in 2025, marked by a 93.40% growth in the regenerative filling materials sector, but with notable disparities among brands [1][2] - The "Matthew Effect" is becoming evident, where leading brands are gaining market share at the expense of smaller competitors, particularly in the context of regulatory barriers and technological advancements [1][10] Regenerative Filling Materials - Regenerative filling materials have emerged as the "MVP" of the year, with a 93.40% increase in sales in 2025, continuing a trend of rapid growth over the past three years [2] - The brand "Zhenai Su Fei" under Aimeike leads with a remarkable 463% growth, while "Yiyan Shi" from Huadong Pharmaceutical, once a market leader, has seen a 56% decline [2][3] - Despite the growth of "Zhenai Su Fei," its contribution to Aimeike's overall performance remains uncertain, as the company reported over a 20% decline in revenue and net profit in the first three quarters of 2025 [2] Market Dynamics - The decline of "Yiyan Shi" is attributed to its earlier market entry leading to reduced novelty among consumers, and some users seeking alternative products after initial experiences [3] - The market for ultrasonic devices, once a star in anti-aging treatments, has seen a 55.2% drop in sales, indicating a shift in consumer preferences and budget constraints [4][8] - In contrast, the "Meila Meisheng" ultrasonic knife has gained popularity, with a 147.22% increase in sales, appealing to users aged 35 and above [4][5] Competitive Landscape - The competitive landscape is tightening, with head brands further squeezing the market space for smaller brands, as consumers tend to prefer established, reliable products [4] - The decline in ultrasonic device sales is not solely due to the emergence of new technologies but also reflects market misuse and consumer fatigue [7][10] Hyaluronic Acid Market - Hyaluronic acid remains a top-selling product, with a 19.70% increase in sales in 2025, despite facing challenges such as oversupply and intense price competition [8][9] - The product's versatility and ability to cater to a wide range of consumer needs contribute to its sustained popularity, positioning it as a mainstay in the anti-aging market [9] Future Growth Areas - The market is transitioning towards specialized segments, with a focus on individual needs and the emergence of new growth areas such as recombinant collagen products, hair loss treatments, and weight management [10][11] - The recombinant collagen market is projected to grow at a compound annual growth rate of 41.4% from 2023 to 2027, indicating strong potential for expansion [10]

Market Overview - The medical beauty sector experienced a decline of 1.27% on February 13, with *ST Meigu leading the drop [1] - The Shanghai Composite Index closed at 4082.07, down 1.26%, while the Shenzhen Component Index closed at 14100.19, down 1.28% [1] Stock Performance - Key stocks in the medical beauty sector showed the following performance: - Jinbo Biological (920982) closed at 217.52, down 0.45% with a trading volume of 3504.16 and a transaction amount of 76.71 million [1] - Aimeike (300896) closed at 145.24, down 1.10% with a trading volume of 22,600 and a transaction amount of 3.32 billion [1] - Huaxi Biological (688363) closed at 47.25, down 1.42% with a trading volume of 34,500 and a transaction amount of 164 million [1] - *ST Meigu (000615) closed at 3.26, down 1.81% with a trading volume of 111,200 and a transaction amount of 36.89 million [1] Capital Flow - The medical beauty sector saw a net outflow of 55.91 million from main funds, while retail investors contributed a net inflow of 21.01 million [1] - Detailed capital flow for key stocks includes: - *ST Meigu: Main funds net outflow of 3.25 million, retail net inflow of 1.37 million [2] - Jinbo Biological: Main funds net outflow of 10.75 million, retail net outflow of 1.08 million [2] - Huaxi Biological: Main funds net outflow of 13.55 million, retail net inflow of 12.55 million [2] - Aimeike: Main funds net outflow of 39.11 million, retail net inflow of 7.09 million [2]

Recent Events - The arbitration case between the company's subsidiary REGEN and Datoo regarding the agency rights for the AestheFill product is still under review. On January 30, 2026, the Shenzhen International Arbitration Court revoked the previous temporary sales restriction on REGEN, but the final outcome of the case has not yet been announced, which may impact the company's future business layout [2]. Business Development - The company is accelerating its diversification efforts, with the anti-hair loss product Minoxidil having obtained a drug registration certificate and is advancing in market promotion. The bone structure beauty filler product "Gekela" has received positive market feedback. These new products may become future growth points, although specific sales targets have not been publicly disclosed [3]. Financial Performance - In the first three quarters of 2025, the company reported revenue of 1.865 billion yuan and a net profit attributable to shareholders of 1.093 billion yuan, representing year-on-year declines of 21.49% and 31.05%, respectively. The gross profit margin remains high at 93.36%. The ongoing pressure on performance is attributed to intensified industry competition [4]. Stock and Capital Performance - Recent stock price fluctuations have been significant, with two large block trades occurring on February 3, 2026, at a transaction price of 113 yuan per share, reflecting a discount of 23.43%. On February 5, the stock price increased by 5.09% to 155.87 yuan per share. The flow of funds and changes in institutional holdings may reflect market sentiment [5].